Dacarbazine
Research News and Information

Wednesday, March 17, 2010

Increased vulnerability of the spinal cord to radiation or intrathecal chemotherapy during adolescence: A report from the Children's Oncology Group.

13 Dec 2009 PURPOSE: To assess the rate of spinal cord toxicity in adolescents resulting from chemoradiotherapy of parameningeal sarcoma. METHODS AND MATERIALS: Of 152 patients with parameningeal sarcoma treated per the Intergroup Rhabdomyosarcoma Study Group ... Read more...

Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?

13 Dec 2009 Alveolar rhabdomyosarcoma (RMS) of the extremity is not infrequently associated with regional node metastasis. Knowledge of lymphatic drainage of extremity RMSs is important to determine radiotherapy fields. In this report we describe two patients ... Read more...

Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.

29 Nov 2009 BACKGROUND: The prognosis for recurrent/progressive Ewing sarcoma (ES) remains poor. Pre-clinical, adult phase I and II trials have demonstrated the combination of irinotecan and temozolomide to have schedule-dependent synergy and significant ... Read more...

Latest indexed articles for 'Dacarbazine'

These are the very latest articles for this heading:

• Increased vulnerability of the spinal cord to radiation or intrathecal chemotherapy during adolescence: A report from the Children's Oncology Group. 13 Dec 2009
• Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk? 13 Dec 2009
• Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. 29 Nov 2009
• Nodular lymphocyte predominant Hodgkin lymphoma with clusters of LP Cells, acute inflammation, and fibrosis: a syncytial variant. 30 Oct 2009
• Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors. 29 Sep 2009
• Recognition of O6MeG lesions by MGMT and mismatch repair proficiency may be a prerequisite for low-dose radiation hypersensitivity. 29 Sep 2009
• Non-Hodgkin lymphoma following temozolomide. 29 Sep 2009
• Unintended pregnancy after gonadal failure chemoprevention with gonadotropin-releasing hormone agonist in women with hematologic malignancies. Sep 2009
• Recurrent PNET with MGMT methylation responds to temozolomide. 30 Aug 2009
• Population-based study of pseudoprogression after chemoradiotherapy in GBM. 30 Aug 2009
• Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. 30 Aug 2009
• A rare case of aplastic anemia caused by temozolomide. 30 Aug 2009
• Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. 30 Aug 2009
• Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. 22 Aug 2009
• Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. 16 Aug 2009
• Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. 2 Aug 2009
• Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas. 2 Aug 2009
• [Recent trends in the pathophysiology and treatment of pituitary adenomas] 30 Jul 2009
• Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine. 30 Jul 2009
• First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity. 30 Jul 2009

See a longer list of these articles.

Technical information about 'Dacarbazine'

Definition: An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)

Chemical name: 1H-Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-

Registry Number: 4342-03-4

Descriptor UI: D003606

Alternative terms: Dacarbazine; Decarbazine; DIC; Dimethyl Triazeno Imidazole Carboxamide; DTIC; ICDT; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; Dimethyl Imidazole Carboxamide; Carboxamide, Dimethyl Imidazole; Imidazole Carboxamide, Dimethyl; NSC-45388; NSC 45388; NSC45388; DTIC-Dome; DTIC Dome; DTICDome; Biocarbazine; Deticene;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antineoplastic Agents, Alkylating;

Tree Number: D02.925.200; D03.383.129.308.240;

History Note: 80(75)